BeyondSpring (NASDAQ:BYSI) Releases Earnings Results, Beats Expectations By $0.49 EPS

Posted by Chris Copeland on Mar 27th, 2026

BeyondSpring (NASDAQ:BYSI – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.49, FiscalAI reports.

BeyondSpring Price Performance

Shares of BeyondSpring stock opened at $1.61 on Friday. BeyondSpring has a 1-year low of $0.98 and a 1-year high of $3.44. The company has a market capitalization of $64.93 million, a PE ratio of -10.73 and a beta of 0.56. The business has a 50-day moving average of $1.52 and a 200-day moving average of $1.75.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BeyondSpring stock. State Street Corp acquired a new position in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned about 0.57% of BeyondSpring as of its most recent SEC filing. 40.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of BeyondSpring in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Check Out Our Latest Report on BeyondSpring

About BeyondSpring

(Get Free Report)

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.